Rasna Therapeutics IncOTC Pink - Current Information:RASP
- LAST PRICE0.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rasna Therapeutics Inc | 15.4M | -2.4x | --- |
Galecto Inc | 15.5M | -0.3x | --- |
Aprea Therapeutics Inc | 15.6M | -0.7x | --- |
CalciMedica Inc | 15.2M | -0.1x | --- |
Microbot Medical Inc | 15.8M | -0.9x | --- |
Better Therapeutics Inc | 14.6M | -0.2x | --- |
Company Information
Rasna Therapeutics, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. Its clinical program is based around three druggable intervention points with potential to improve safety and efficacy of AML therapies. The Company develops small molecule drug candidates targeting two genes: nucleophosmin-1 (NPM1) and lysine specific demethylase-1 (LSD1). Its product candidates include RASP-201 and RASP-301. Its the lead reversible LSD-1 candidate, RASP-201 is an orally dosed, selective reversible inhibitor of lysine-specific demethylase, or LSD1, a pathway that blocks differentiation and confers a poor prognosis to AML. The Company's product candidate, RASP-301, is an oral, small molecule inhibitor that in preclinical studies to disrupt NPM1 oligomerization and has the potential to treat refractory AML with reduced toxicity at low dose levels.
Contact Information
- Headquarters
- 420 Lexington Ave Ste 2525NEW YORK, NY, United States 10170-2599
- Phone
- 646-396-4087
- Fax
- ---
Executives
- Independent Chairman of the Board
- Willy Simon
- Finance Director
- Keeren Shah
- Independent Director
- John Brancaccio
- Independent Director
- Gary Jacob
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 771.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $-0.01 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
